Antibody Response to Pneumocystis jirovecii

Details

• Alternative Title:
  Emerg Infect Dis
• Personal Author:
  Daly, Kieran R. ; Huang, Laurence ; Morris, Alison ; Koch, Judy ; Crothers, Kristina ; Levin, Linda ; Eiser, Shary ; Satwah, Supriya ; Zucchi, Patrizia ; Walzer, Peter D.
• Description:
  We conducted a prospective pilot study of the serologic responses to overlapping recombinant fragments of the Pneumocystis jirovecii major surface glycoprotein (Msg) in HIV-infected patients with pneumonia due to P. jirovecii and other causes. Similar baseline geometric mean antibody levels to the fragments measured by an ELISA were found in both groups. Serum antibodies to MsgC in P. jirovecii patients rose to a peak level 3-4 weeks (p<0.001) after recovery from pneumocystosis; baseline CD4+ count > or =50 cells/microL and first episode of pneumocystosis were the principal host factors associated with this rise (both p<0.001). Thus, MsgC shows promise as a serologic reagent and should be tested further in clinical and epidemiologic studies.
• Subjects:
  Acquired Immune Deficiency Syndrome (AIDS) Adult AIDS-Related Opportunistic Infections Antibodies, Fungal CD4+ Cells Enzyme-Linked Immunosorbent Assay Enzyme-linked Immunosorbent Assay (ELISA) Female First Episode Pneumocystosis Fungal Proteins HIV Infections Human Immunodeficiency Virus (HIV) Humans Major Surface Glycoprotein (Msg) Male Membrane Glycoproteins Middle Aged Pneumocystis Jirovecii Pneumocystis Pneumonia Pneumonia, Pneumocystis Recombinant Antigens Research Serum Antibody Responses

  More +
• Source:
  Emerg Infect Dis. 12(8):1231-1237.
• Document Type:
  Journal Article
• Volume:
  12
• Issue:
  8
• Collection(s):
  Emerging Infectious Diseases
• Main Document Checksum:
  urn:sha256:eaa23943d47e6ba5f4cb5bb7926d5492cc49dc876937634121a0e40d875bd4b9
• Download URL:
  https://stacks.cdc.gov/view/cdc/16251/cdc_16251_DS1.pdf
• File Type:
  [PDF - 227.71 KB ]